Clinical Trial Search

Primary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm — 89.4; 92.9 percentage of participants…

Primary: The Go/No-Go Task Percentage Assessed by fMRI — 91.7; 97.0; 88.7; 87.9 percentage correct responses/inhibitions

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 126; 134; 596; 61 Participants

Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants

Primary: Change From Baseline in Intraocular Pressure — -4.30; -4.57; -4.76; -4.79 mm Hg — p=<0.001

Primary: Maximum Plasma Concentration (Cmax) — 42.4; 66.5 mg/L

Primary: Number of Patients Without Major Adverse Events Within 30 Days — 62 Participants

Primary: Number of ABI Complications — 2 Events

Primary: Percentage of Participants Achieving Objective Response Rate (ORR) (Complete Response + Partial Response) — 10; 6; 7 Percentage of Participants

Primary: Feasibility of Retention/ Adherence — 15; 17 Participants

Primary: Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks. — 0; 2; 1; 2 Participants

Primary: Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase — 2.24; 2.33; 2.32; 1.84 ln (seizures per 28 days)…

Primary: Patient Survival — 109; 104 Participants

Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 20; 37 Participants

Primary: Number of Participants With First-skin Puncture Success — 244; 229 Participants